Michal Ciborowski

Dr. Michal Ciborowski

Clinical Research Centre
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MSMichal Szeremeta
Michal Szeremeta
KPKarolina Pietrowska
Karolina Pietrowska
Anna Niemcunowicz-JanicaAnna Niemcunowicz-Janica
Anna Niemcunowicz-Janica
AKAdam Krętowski
Adam Krętowski
Michal CiborowskiMichal Ciborowski
Michal Ciborowski
Forensic toxicology and forensic medicine are unique among all other medical fields because of their essential legal impact, especially in civil and criminal cases. New high-throughput technologies, borrowed from chemistry and physics, have proven that metabolomics, the youngest of the “omics sciences”, could be one of the most powerful tools for monitoring changes in forensic disciplines. Metabolomics is a particular method that allows for the measurement of metabolic changes in a multicellular system using two different approaches: targeted and untargeted. Targeted studies are focused on a known number of defined metabolites. Untargeted metabolomics aims to capture all metabolites present in a sample. Different statistical approaches (e.g., uni- or multivariate statistics, machine learning) can be applied to extract useful and important information in both cases. This review aims to describe the role of metabolomics in forensic toxicology and in forensic medicine.

29 June 2015 in Journal of Proteome Research
Verified
Journal Article
Closed access
Joanna Barbara GodzienJoanna Barbara Godzien
Joanna Barbara Godzien
Michal CiborowskiMichal Ciborowski
Michal Ciborowski
MMMaría Paz Martínez-Alcázar
María Paz Martínez-Alcázar
PSPaulina Samczuk
Paulina Samczuk
AKAdam Krętowski
Adam Krętowski
CBCoral Barbas
Coral Barbas

29 January 2017
Verified
Book Chapter
Closed access
PDF file
EAEmily Grace Armitage
Emily Grace Armitage
Michal CiborowskiMichal Ciborowski
Michal Ciborowski

24 February 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Michal CiborowskiMichal Ciborowski
Michal Ciborowski
JTJoanna Teul
Joanna Teul
JMJose Luis Martín-Ventura
Jose Luis Martín-Ventura
JEJesús Egido
Jesús Egido
CBCoral Barbas
Coral Barbas
Abdominal aortic aneurysm (AAA) is a permanent and localized aortic dilation, defined as aortic diameter ≥3 cm. It is an asymptomatic but potentially fatal condition because progressive enlargement of the abdominal aorta is spontaneously evolving towards rupture. Biomarkers may help to explain pathological processes of AAA expansion, and allow us to find novel therapeutic strategies or to determine the efficiency of current therapies. Metabolomics seems to be a good approach to find biomarkers of AAA. In this study, plasma samples of patients with large AAA, small AAA, and controls were fingerprinted with LC-QTOF-MS. Statistical analysis was used to compare metabolic fingerprints and select metabolites that showed a significant change. Results presented here reveal that LC-QTOF-MS based fingerprinting of plasma from AAA patients is a very good technique to distinguish small AAA, large AAA, and controls. With the use of validated PLS-DA models it was possible to classify patients according to the disease stage and predict properly the stage of additional AAA patients. Identified metabolites indicate a role for sphingolipids, lysophospholipids, cholesterol metabolites, and acylcarnitines in the development and progression of AAA. Moreover, guanidinosuccinic acid, which mimics nitric oxide in terms of its vasodilatory action, was found as a strong marker of large AAA.


21 August 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
AHAhsan Hameed
Ahsan Hameed
MGMauro Galli
Mauro Galli
EAEdyta Adamska-Patruno
Edyta Adamska-Patruno
AKAdam Krętowski
Adam Krętowski
Michal CiborowskiMichal Ciborowski
Michal Ciborowski
Berries are considered “promising functional fruits” due to their distinct and ubiquitous therapeutic contents of anthocyanins, proanthocyanidins, phenolic acids, flavonoids, flavanols, alkaloids, polysaccharides, hydroxycinnamic, ellagic acid derivatives, and organic acids. These polyphenols are part of berries and the human diet, and evidence suggests that their intake is associated with a reduced risk or the reversal of metabolic pathophysiologies related to diabetes, obesity, oxidative stress, inflammation, and hypertension. This work reviewed and summarized both clinical and non-clinical findings that the consumption of berries, berry extracts, purified compounds, juices, jams, jellies, and other berry byproducts aided in the prevention and or otherwise management of type 2 diabetes mellitus (T2DM) and related complications. The integration of berries and berries-derived byproducts into high-carbohydrate (HCD) and high-fat (HFD) diets, also reversed/reduced the HCD/HFD-induced alterations in glucose metabolism-related pathways, and markers of oxidative stress, inflammation, and lipid oxidation in healthy/obese/diabetic subjects. The berry polyphenols also modulate the intestinal microflora ecology by opposing the diabetic and obesity rendered symbolic reduction of Bacteroidetes/Firmicutes ratio, intestinal mucosal barrier dysfunction-restoring bacteria, short-chain fatty acids, and organic acid producing microflora. All studies proposed a number of potential mechanisms of action of respective berry bioactive compounds, although further mechanistic and molecular studies are warranted. The metabolic profiling of each berry is also included to provide up-to-date information regarding the potential anti-oxidative/antidiabetic constituents of each berry.